Jason Ward

So there's a lot of private investment that would come to Ireland if we opened up the markets, provided planning, provided data center space and green energy.

They would come and build and contribute to the grid and enable new companies to develop what's called agentic AI.

So AI and large language model training, I think we've sort of missed the boat there.

But when you get into AI inferencing, we certainly have the capacity to really lead the field there.

You mentioned on the show earlier, Joe, around the pharmaceutical industry.

Ireland is home to some of the world's leading clinical trial pharmaceutical companies.

If you think about the possibilities for AI for new clinical trials, drug development, we could certainly play a part in that space and maybe differentiate Ireland as a leader in this field and attract a huge amount of organisations that are going to develop in that field.

DeepMind, Denis Abibas has just developed his company, Isomorphic, who are developing new drugs to help cancer screening, Alzheimer's, all of these, you know, that diseases that are in the marketplace today, AI, agentic AI can provide solutions

to eradicate diseases like that.

And Ireland could become a leader in that field.

I think that's back to the differentiation, Joe.

So there's a lot of what we call neoclouds.

So you'll remember the hyperscalers, Google, Microsoft, Amazon, and so on.

Well, there's a new breed of GPU providers.

So you call these guys neoclouds.

And effectively, these provide GPU services or GPU as a service where you can go in and rent GPUs to run AI workloads and routines.

So that's sort of like a one streamer, one pillar of AI performance.

But the huge benefit is going to come in AI inferencing.

It's about a $500 billion market over the next five years.

And that's where enterprises and customers actually get the benefit of AI.